Your browser doesn't support javascript.
loading
Patient-reported outcomes for patients with breast cancer undergoing radiotherapy: A single-center registry experience.
Laughlin, Brady S; Bhangoo, Ronik S; Thorpe, Cameron S; Golafshar, Michael A; DeWees, Todd A; Anderson, Justin D; Vern-Gross, Tamara Z; McGee, Lisa A; Wong, William W; Halyard, Michele Y; Keole, Sameer R; Vargas, Carlos E.
Afiliación
  • Laughlin BS; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Bhangoo RS; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Thorpe CS; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Golafshar MA; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, United States.
  • DeWees TA; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, United States.
  • Anderson JD; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Vern-Gross TZ; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • McGee LA; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Wong WW; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Halyard MY; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Keole SR; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
  • Vargas CE; Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
Front Oncol ; 12: 920739, 2022.
Article en En | MEDLINE | ID: mdl-36091145
ABSTRACT

Background:

We present Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for patients undergoing adjuvant radiotherapy for breast cancer with curative intent. We describe the frequency and severity of PRO-CTCAE and analyze them with respect to dose fractionation.

Methods:

Patients were included in this study if they were treated with curative intent for breast cancer and enrolled on a prospective registry. Patients must have completed at least one baseline and one post-radiation survey that addressed PRO-CTCAE. For univariate and multivariate analysis, categorical variables were analyzed by Fisher's exact test and continuous variables by Wilcoxon rank sum test. PRO-CTCAE items graded ≥2 and ≥3 were analyzed between patients who received hypofractionation (HF) versus standard conventional fractionation (CF) therapy by the Chi-square test.

Results:

Three hundred thirty-one patients met inclusion criteria. Pathologic tumor stage was T1-T2 in 309 (94%) patients. Eighty-seven (29%) patients were node positive. Two hundred forty-seven patients (75%) experienced any PRO-CTCAE grade ≥2, and 92 (28%) patients experienced any PRO-CTCAE grade ≥3. CF was found to be associated with an increased risk of grade ≥3 skin toxicity, swallowing, and nausea (all p < 0.01). HF (OR 0.48, p < 0.01) was significant in the multivariate model for decreased risk of any occurrence of PRO-CTCAE ≥3.

Conclusions:

Our study reports one of the first clinical experiences utilizing multiple PRO-CTCAE items for patients with breast cancer undergoing radiation therapy with curative intent. Compared with CF, HF was associated with a significant decrease in any PRO-CTCAE ≥3 after multivariate analysis.
Palabras clave

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos